GIPR and type 2 diabetes mellitus: They interact with their cognate receptors (GIPR and GLP-1R), which are both members of the class B G protein-coupled receptors (GPCRs) and are already recognized as targets for the treatment of metabolic diseases, such as type 2 diabetes mellitus (T2DM) and obesity.